Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer
Recently, clinical evidence has raised BMI as an emerging prognostic factor for immunotherapy, regardless of cancer types. In this article we rewirw current data about correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer